- Home
- NUVL vs RYTM Comparison
NUVL vs RYTM Comparison
Compare NUVL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- RYTM
- Stock Information
- Founded
- NUVL 2017
- RYTM 2008
- Country
- NUVL United States
- RYTM United States
- Employees
- NUVL N/A
- RYTM N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- NUVL Health Care
- RYTM Health Care
- Exchange
- NUVL Nasdaq
- RYTM Nasdaq
- Market Cap
- NUVL 7.1B
- RYTM 6.4B
- IPO Year
- NUVL 2021
- RYTM 2017
- Fundamental
- Price
- NUVL $109.19
- RYTM $101.26
- Analyst Decision
- NUVL Strong Buy
- RYTM Strong Buy
- Analyst Count
- NUVL 13
- RYTM 12
- Target Price
- NUVL $133.85
- RYTM $117.00
- AVG Volume (30 Days)
- NUVL 734.4K
- RYTM 698.1K
- Earning Date
- NUVL 10-30-2025
- RYTM 11-04-2025
- Dividend Yield
- NUVL N/A
- RYTM N/A
- EPS Growth
- NUVL N/A
- RYTM N/A
- EPS
- NUVL N/A
- RYTM N/A
- Revenue
- NUVL N/A
- RYTM $174,334,000.00
- Revenue This Year
- NUVL N/A
- RYTM $46.10
- Revenue Next Year
- NUVL N/A
- RYTM $63.02
- P/E Ratio
- NUVL N/A
- RYTM N/A
- Revenue Growth
- NUVL N/A
- RYTM 54.92
- 52 Week Low
- NUVL $55.54
- RYTM $45.91
- 52 Week High
- NUVL $112.88
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- NUVL 66.08
- RYTM 46.32
- Support Level
- NUVL $93.05
- RYTM $99.44
- Resistance Level
- NUVL $112.53
- RYTM $102.13
- Average True Range (ATR)
- NUVL 5.84
- RYTM 5.12
- MACD
- NUVL 1.06
- RYTM -0.36
- Stochastic Oscillator
- NUVL 84.34
- RYTM 29.74
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.